Breaking News, Collaborations & Alliances

Catalyst Grants Kye Exclusive Canadian Commercial Rights to AGAMREE

Catalyst will supply the product to Kye, which will assume full responsibility for obtaining regulatory approval for the novel corticosteroid.

Author Image

By: Charlie Sternberg

Associate Editor

Catalyst Pharmaceuticals Inc., a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has entered into a License, Supply, and Commercialization Agreement with Kye Pharmaceuticals Inc., granting Kye the exclusive Canadian commercial rights to AGAMREE (vamorolone), a novel corticosteroid for the treatment of Duchenne Muscular Dystrophy (DMD) and potentially other indication...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters